Literature DB >> 19632987

Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence.

Benedetta Savino1, Elena Monica Borroni, Nina Machado Torres, Paul Proost, Sofie Struyf, Anneleen Mortier, Alberto Mantovani, Massimo Locati, Raffaella Bonecchi.   

Abstract

The chemokine decoy receptor D6 controls inflammatory responses by selective recognition and degradation of most CCR1 to CCR5 agonistic ligands. CCL14 is a homeostatic chemokine present at high concentrations in the serum with a weak agonist activity on CCR1. Under inflammatory conditions, plasmin and UPA-mediated truncation of 8 amino acids generates the potent CCR1/CCR3/CCR5 isoform CCL14(9-74), which is further processed and inactivated by dipeptidyl peptidase IV/CD26 that generates CCL14(11-74). Here we report that D6 efficiently binds both CCL14 and its truncated isoforms. Like other D6 ligands, the biologically active CCL14(9-74) induces adaptive up-regulation of D6 expression on the cell membrane and is rapidly and efficiently degraded. In contrast, the D6-mediated degradation of the biologically inactive isoforms CCL14(1-74) and CCL14(11-74) is very inefficient. Thus, D6 cooperates with CD26 in the negative regulation of CCL14 by the selective degradation of its biologically active isoform. Analysis of a panel of CC chemokines and their truncated isoforms revealed that D6-mediated chemokine degradation does not correlate with binding affinity. Conversely, degradation efficiency is positively correlated with D6 adaptive up-regulation. Sequence analysis indicated that a proline residue in position 2 of D6 ligands is dispensable for binding but crucial for D6 adaptive up-regulation and efficient degradation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632987      PMCID: PMC2758019          DOI: 10.1074/jbc.M109.029249

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

2.  The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors.

Authors:  R J Nibbs; E Kriehuber; P D Ponath; D Parent; S Qin; J D Campbell; A Henderson; D Kerjaschki; D Maurer; G J Graham; A Rot
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.

Authors:  Cédric Blanpain; Benjamin J Doranz; Antoine Bondue; Cédric Govaerts; Anne De Leener; Gilbert Vassart; Robert W Doms; Amanda Proudfoot; Marc Parmentier
Journal:  J Biol Chem       Date:  2002-12-03       Impact factor: 5.157

Review 4.  Regulation of the immune response by the interaction of chemokines and proteases.

Authors:  Sofie Struyf; Paul Proost; Jo Van Damme
Journal:  Adv Immunol       Date:  2003       Impact factor: 3.543

Review 5.  Hemofiltrate CC chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15.

Authors:  U Forssmann; H J Mägert; K Adermann; S E Escher; W G Forssmann
Journal:  J Leukoc Biol       Date:  2001-09       Impact factor: 4.962

6.  Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.

Authors:  J Vakili; L Ständker; M Detheux; G Vassart; W G Forssmann; M Parmentier
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

7.  n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation.

Authors:  Ulf Forssmann; Inka Hartung; Ralf Bälder; Barbara Fuchs; Sylvia E Escher; Nikolaj Spodsberg; Yasmin Dulkys; Michael Walden; Aleksandra Heitland; Armin Braun; Wolf-Georg Forssmann; Jörn Elsner
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

8.  The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.

Authors:  Stefania Vetrano; Elena M Borroni; Adelaida Sarukhan; Benedetta Savino; Raffaella Bonecchi; Carmen Correale; Vincenzo Arena; Massimo Fantini; Massimo Roncalli; Alberto Malesci; Alberto Mantovani; Massimo Locati; Silvio Danese
Journal:  Gut       Date:  2009-10-20       Impact factor: 23.059

9.  Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor.

Authors:  Raffaella Bonecchi; Massimo Locati; Emanuela Galliera; Marisa Vulcano; Marina Sironi; Anna M Fra; Marco Gobbi; Annunciata Vecchi; Silvano Sozzani; Bodduluri Haribabu; Jo Van Damme; Alberto Mantovani
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

10.  Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties.

Authors:  M Detheux; L Ständker; J Vakili; J Münch; U Forssmann; K Adermann; S Pöhlmann; G Vassart; F Kirchhoff; M Parmentier; W G Forssmann
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

View more
  19 in total

Review 1.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

Review 2.  Emerging concepts and approaches for chemokine-receptor drug discovery.

Authors:  Morgan O'Hayre; Catherina L Salanga; Tracy M Handel; Damon J Hamel
Journal:  Expert Opin Drug Discov       Date:  2010-11       Impact factor: 6.098

3.  Transgenic expression of murine chemokine decoy receptor D6 by islets reveals the role of inflammatory CC chemokines in the development of autoimmune diabetes in NOD mice.

Authors:  G-J Lin; S-H Huang; Y-W Chen; D-Y Hueng; W-T Chia; M-W Chien; B L Yen; H-K Sytwu
Journal:  Diabetologia       Date:  2011-05-05       Impact factor: 10.122

4.  Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.

Authors:  Anneleen Mortier; Tamara Loos; Mieke Gouwy; Isabelle Ronsse; Jo Van Damme; Paul Proost
Journal:  J Biol Chem       Date:  2010-07-14       Impact factor: 5.157

Review 5.  DARC and D6: silent partners in chemokine regulation?

Authors:  Chris A H Hansell; Catherine E Hurson; Robert J B Nibbs
Journal:  Immunol Cell Biol       Date:  2010-12-14       Impact factor: 5.126

Review 6.  Immune regulation by atypical chemokine receptors.

Authors:  Robert J B Nibbs; Gerard J Graham
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

Review 7.  Atypical chemokine receptors.

Authors:  Maria Helena Ulvmar; Elin Hub; Antal Rot
Journal:  Exp Cell Res       Date:  2011-01-25       Impact factor: 3.905

8.  CCR2 acts as scavenger for CCL2 during monocyte chemotaxis.

Authors:  Silvia Volpe; Elisabetta Cameroni; Barbara Moepps; Sylvia Thelen; Tiziana Apuzzo; Marcus Thelen
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

Review 9.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

Review 10.  Initial afferent lymphatic vessels controlling outbound leukocyte traffic from skin to lymph nodes.

Authors:  Alvaro Teijeira; Ana Rouzaut; Ignacio Melero
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.